Conclusion of a non-exclusive rebate agreement under Section 130a(8) SGB V for the active substance Fondaparinux, ATC B01AX05, for the period 01/06/2026–31/05/2028 (plus option to extend once by 12 months)

Summary

The tender concerns a non-exclusive rebate agreement for medicines containing fondaparinux for the period 01/06/2026–31/05/2028, with an option to extend the contract once by 12 months. It is an open accession model: interested pharmaceutical companies may join the agreement if they submit the required documents on time by email. The bidder should note that the exact qualification and compliance requirements are partly available only in the tender documents.